EnteroTarget is a spinout company from the University of Copenhagen and was established in 2018 after the discovery of a novel insulin-based mechanism involved in the regeneration of the colonic epithelial lining. We are partnering up with investors to bring the therapy to market with ulcerative colitis as the primary medical indication and Crohn’s disease as a potential additional indication by 2028. EnteroTarget holds the exclusive worldwide license to the invention, and we own patents in the EU and the US. Currently, we are running a phase 1 clinical trial and are preparing for a phase 2 clinical trial in 2023 to meet the milestones in the ambitious business plan.